Ionetix Corp / DE /

What the company does

No publishable business summary is available from the effective-prospectus read.

Use of proceeds

We will not receive any proceeds from the sale of the shares of common stock offered by the selling stockholders.

Underwriters

The completed effective-prospectus read stated no underwriters.

Extracted from S-1/A 0001213900-26-117736, filed Nov 10, 2026 and verified against that filing text.

Key risk factors

• Losses and profitability risk

  “We have incurred losses since inception, and may continue to incur losses for the foreseeable future, which raises substantial doubt about our ability to achieve or sustain profitability.”

• Additional capital requirements

  “We will require additional capital to fund our operations, and such financing may not be available on acceptable terms, if at all.”

• Going concern uncertainty

  “Our auditor’s report includes a “going concern” explanatory paragraph.”

• Indebtedness restrictions

  “If we incur indebtedness under future credit facilities, the associated covenants and repayment obligations could restrict our operations and adversely affect our financial condition.”

• Competitive market

  “We operate in a highly competitive market for the manufacturing and sale of radioactive isotopes, and we may be unable to compete effectively against companies with greater resources, more established commercial infrastructure, or more advanced technologies.”

• No established trading market

  “There is not now and never has been any market for our securities and an active market may never develop.”

• Listing and quotation uncertainty

  “However, we may not be successful in having our shares quoted on an over-the-counter market or listed on a national securities exchange.”